Abstract
No public abstract is available from the verified source records.
Neil S. Dogra, Robert T. Sataloff
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Immune checkpoint inhibitors and cardiovascular toxicity
10.1016/s1470-2045(18)30457-1 · 2018
Autoimmune complications of immunotherapy: pathophysiology and management
10.1136/bmj.m736 · 2020
The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients
10.1111/imr.13270 · 2023
Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human
10.1111/imr.13240 · 2023
How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis
10.1002/ijc.35347 · 2025
Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study
10.1002/bcp.70700 · 2026
Immune-Related Oral, Otologic, and Ocular Adverse Events
2020
Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
10.1136/jitc-2020-001675 · 2020
Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report
10.1097/cji.0000000000000310 · 2020
Immune checkpoint inhibitor induced supraglottitis: a case series
10.1002/lary.31492 · 2024
Laryngeal mucous membrane pemphigoid as an immune-related adverse effect of pembrolizumab treatment
10.1016/j.jvoice.2022.12.028 · 2025
Paraneoplastic bilateral vocal cord paralysis in a patient with anti-Hu syndrome after receiving nivolumab: case report and literature review
10.1016/j.jneuroim.2025.578679 · 2025
Clinical practice guideline: Hoarseness (Dysphonia) (Update)
2018
I go but i don’t participate”: a scoping review with thematic synthesis of the experiences of voice disorders in adulthood
10.1016/j.jvoice.2026.06.013 · 2026
Self-reported impact of dysphonia in a primary care population: an epidemiological study
10.1002/lary.21058 · 2010
Pneumonia, mortality, and other outcomes associated with unsafe swallowing detected via fiberoptic endoscopic evaluation of swallowing (FEES) in patients with functional oropharyngeal dysphagia: a systematic review and meta-analysis
10.1007/s00455-022-10427-3 · 2022
Dysphagia in hospitalized patients: prevalence, related factors and impact on aspiration pneumonia and mortality
10.1111/eci.13930 · 2023
Safety and efficacy of programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the treatment of cancer: an overview of systematic reviews
10.3389/fimmu.2022.953761 · 2022
Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers
10.1001/jamaoncol.2021.4971 · 2021
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes
10.1016/s1474-4422(23)00369-1 · 2024
Neurologic adverse events of immune checkpoint inhibitors: a systematic review
10.1212/wnl.0000000000011795 · 2021
Cranial nerve disorders associated with immune checkpoint inhibitors
10.1212/wnl.0000000000011340 · 2021
Unilateral vocal cord paralysis: a comprehensive guide for general radiologists
10.1016/j.ejrad.2026.113053 · 2026
Orofacial complications from immune checkpoint inhibitors: a retrospective analysis from two academic medical centers
10.1002/hed.27646 · 2024
Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
10.1111/odi.13964 · 2022
Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber
2021
Immune checkpoint inhibitor-induced colitis: diagnosis and management
10.1007/s11523-017-0495-4 · 2017
Severe oral ulcers associated with nivolumab treatment
10.1001/jamadermatol.2016.4443 · 2017
Pembrolizumab-induced pan-airway mucositis with a cobblestone-like appearance: a case report
10.1093/jjco/hyag016 · 2026
Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies: ISOO/MASCC/ASCO guideline
10.1200/jco.21.01208 · 2021
Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis
10.6004/jnccn.2020.7675 · 2021
Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases
10.1080/14740338.2024.2416539 · 2026
Orofacial adverse events associated with immune checkpoint inhibitors: using a large real-world dataset
10.1016/j.oooo.2025.09.006 · 2026
Laryngitis: types, causes, and treatments
10.1016/j.otc.2007.11.011 · 2008
Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer
10.1002/lary.28038 · 2020
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors
10.1016/j.ejca.2022.11.001 · 2023
Cancer knocks you out by fasting: cachexia as a consequence of metabolic alterations in cancer
10.1002/jcp.31417 · 2025
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
10.1200/jco.21.01440 · 2021
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients
10.1007/s00262-023-03436-0 · 2023
No additional external references are available.